title: GastroPanel® test for non-invasive diagnosis of atrophic gastritis in patients with dyspepsia.
abstract: OBJECTIVE
  Atrophic gastritis (AG), first step in the cascade leading to gastric adenocarcinoma, is related to Helicobacter pylori (H. pylori) infection. Currently, the gold standard for the diagnosis of AG is esophagogastroduodenoscopy (EGD) with histological examination of the biopsy specimens. However, since the latter are taken in random order and the distribution of AG is often patchy, histology is only representative of mucosal status. Considering this limitation, a test named GastroPanel®, that measures the blood concentrations of pepsinogen I and II, gastrin-17 and H. pylori antibodies, has been developed as a potential non-invasive biopsy. Aim of this study has been to assess the accuracy of GastroPanel® in patients with AG.
  
  
  METHODS
  Forty-seven dyspeptic patients (24 males, mean age 52.2±9.3 years), in follow-up for antral or diffuse AG, were enrolled. All underwent at least two EGDs with random biopsies and blood collection for GastroPanel® parameters examination.
  
  
  RESULTS
  Of the 47 patients, 16 (34.1%) had histological diagnosis of antral and 31 (65.9%) multifocal AG; 17 (36.2%) patients had mild and 30 (63.8%) had moderate-severe AG. H. pylori was detected in 39 (82.9%) and intestinal metaplasia was found in all patients. GastroPanel® showed 82.9% sensitivity for the diagnosis of AG and 53.8% for the diagnosis of H. pylori infection. The prediction of advanced atrophy was not sufficiently accurate, neither in patients with antral nor in those with multifocal AG.
  
  
  CONCLUSIONS
  GastroPanel® can be useful for detecting patients with AG. However, it does not reflect the severity of atrophy.
authors.affiliation: Unit of Gastrointestinal Endoscopy "San Paolo" University Hospital, Milan, Italy - rinaldo_pellican@hotmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Masci
authors.forename: R
authors.initials: R
authors.lastname: Pellicano
authors.forename: B
authors.initials: B
authors.lastname: Mangiavillano
authors.forename: C
authors.initials: C
authors.lastname: Luigiano
authors.forename: L
authors.initials: L
authors.lastname: Stelitano
authors.forename: C
authors.initials: C
authors.lastname: Morace
authors.forename: E
authors.initials: E
authors.lastname: Viale
authors.forename: M
authors.initials: M
authors.lastname: Freschi
authors.forename: M
authors.initials: M
authors.lastname: Locatelli
authors.forename: R
authors.initials: R
authors.lastname: Ieri
authors.forename: A
authors.initials: A
authors.lastname: Cavallaro
authors.forename: S
authors.initials: S
authors.lastname: Testoni
authors.forename: P A
authors.initials: PA
authors.lastname: Testoni
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D001706:Biopsy; D004415:Dyspepsia; D016145:Endoscopy, Digestive System; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000473:pathology*; D005755:Gastrins / Q000097:blood; D005757:Gastritis, Atrophic / Q000097:blood / Q000175:diagnosis* / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D016480:Helicobacter pylori / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D020116:Pepsinogen A / Q000097:blood; D020115:Pepsinogen C / Q000097:blood; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D000907:Antibodies, Bacterial; D015415:Biomarkers; D005755:Gastrins; C013550:gastrin 17; D020115:Pepsinogen C; D020116:Pepsinogen A